Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder
Abstract
1. Introduction
2. Materials and Methods
Interventions
3. Results
4. Discussion
Acknowledgments
Author Contributions
Conflicts of Interest
References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®); American Psychiatric Pub: Washington, DC, USA, 2013. [Google Scholar]
- Lecavalier, L. Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. J. Autism Dev. Disord. 2006, 36, 1101–1114. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tonge, B.J.; Einfeld, S.L. Psychopathology and intellectual disability: The Australian child to adult longitudinal study. Int. Rev. Res. Men. Retard. 2003, 26, 61–91. [Google Scholar]
- Samadi, S.A.; Mahmoodizadeh, A.; McConkey, R. A national study of the prevalence of autism among five-year-old children in Iran. Autism 2012, 16, 5–14. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Warren, Z.; Veenstra-VanderWeele, J.; Stone, W.; Bruzek, J.L.; Nahmias, A.S.; Foss-Feig, J.H.; Jerome, R.N.; Krishnaswami, S.; Sathe, N.A.; Glasser, A.M. Therapies for Children with Autism Spectrum Disorders; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, 2011. [Google Scholar]
- McDougle, C.; Scahill, L.; McCracken, J.; Aman, M.; Tierney, E.; Arnold, L.; Freeman, B.; Martin, A.; McGough, J.; Cronin, P. Research units on pediatric psychopharmacology (RUPP) autism network. Background and rationale for an initial controlled study of risperidone. Child Adolesc. Psychiatr. Clin. N. Am. 2000, 9, 201–224. [Google Scholar] [PubMed]
- Myers, S.M. The status of pharmacotherapy for autism spectrum disorders. Expert Opin. Pharmacother. 2007, 8, 1579–1603. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Shea, S.; Turgay, A.; Carroll, A.; Schulz, M.; Orlik, H.; Smith, I.; Dunbar, F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114, e634–e641. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- McCracken, J.T.; McGough, J.; Shah, B.; Cronin, P.; Hong, D.; Aman, M.G.; Arnold, L.E.; Lindsay, R.; Nash, P.; Hollway, J. Risperidone in children with autism and serious behavioral problems. N. Engl. J. Med. 2002, 347, 314–321. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mccracken, J.; Mcgough, J.; Shah, B. Research units on pediatric psychopharmacology autism network, risperidone in childrenwith autism and serious behavior problems. J. Pediatr. 2003, 142, 86–87. [Google Scholar]
- Mohammad Zaheri, F.; Rafiei, S.M.; Rezaei, M.; Bakhshi, E. Effect of pivotal response treatment on social skill of 6–11 years old autistic children of hamedan. Pajouhan Sci. J. 2013, 11, 16–21. [Google Scholar]
- Mohammadzaheri, F.; Koegel, L.K.; Rezaee, M.; Rafiee, S.M. A randomized clinical trial comparison between pivotal response treatment (PRT) and structured applied behavior analysis (ABA) intervention for children with autism. J. Autism Dev. Disord. 2014, 44, 2769–2777. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mohammadzaheri, F.; Koegel, L.K.; Rezaei, M.; Bakhshi, E. A randomized clinical trial comparison between pivotal response treatment (PRT) and adult-driven applied behavior analysis (ABA) intervention on disruptive behaviors in public school children with autism. J. Autism Dev. Disord. 2015, 45, 2899–2907. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mohammad-Zaheri, F.; Rezaei, M.; Rafi’ei, M.; Bakhshi, E.; Gharib, M. Effect of pivotal response treatment method on initiation skill in children with autism. Arch. Rehabil. 2014, 15, 72–77. [Google Scholar]
- Perry, A.; Condillac, R. Evidence-Based Practices for Children and Adolescents with Autism Spectrum Disorders: Review of the Literature and Practice Guide; Children’s Mental Health Ontario: Toronto, ON, Canada, 2003. [Google Scholar]
- Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am. J. Psychiatry 2005, 162, 1361–1369. [Google Scholar]
- Akhondzadeh, S.; Fallah, J.; Mohammadi, M.-R.; Imani, R.; Mohammadi, M.; Salehi, B.; Ghanizadeh, A.; Raznahan, M.; Mohebbi-Rasa, S.; Rezazadeh, S.-A. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34, 32–36. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Nilipour, R. Farsi Aphasia Test; Iran University of Medical Sciences Publisher: Tehran, Iran, 1993; Volume 1372. [Google Scholar]
- Guy, W. The Clinical Global Impression Scale. The Ecdeu Assessment Manual for Psychopharmacology Revised; Publ. No. ADM 76-338; US Department of Health Education, and Welfare: Rockville, MD, USA, 1976; Volume DHEW, pp. 218–222. [Google Scholar]
- Scahill, L.; Aman, M.G.; McDougle, C.J.; Arnold, L.E.; McCracken, J.T.; Handen, B.; Johnson, C.; Dziura, J.; Butter, E.; Sukhodolsky, D. Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. J. Autism Dev. Disord. 2009, 39, 720–729. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Koegel, LK. Pivotal Response Treatment®: Using Motivation as a Pivotal Response; Behavior Management Student Organization: Santa Barbara, CA, USA, 2011. [Google Scholar]
- Nelson, K.E.; Camarata, S.M.; Welsh, J.; Butkovsky, L.; Camarata, M. Effects of imitative and conversational recasting treatment on the acquisition of grammar in children with specific language impairment and younger language-normal children. J. Speech Lang. Hear. Res. 1996, 39, 850–859. [Google Scholar] [CrossRef] [Scilit]
- Harper, C.B.; Symon, J.B.; Frea, W.D. Recess is time-in: Using peers to improve social skills of children with autism. J. Autism Dev. Disord. 2008, 38, 815–826. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Aman, M.G.; Mcdougle, C.J.; Scahill, L.; Handen, B.; Arnold, L.E.; Johnson, C.; Stigler, K.A.; Bearss, K.; Butter, E.; Swiezy, N.B. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. J. Am. Acad. Child Adolesc. Psychiatry 2009, 48, 1143–1154. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- McDougle, C.J.; Scahill, L.; Aman, M.G.; McCracken, J.T.; Tierney, E.; Davies, M.; Arnold, L.E.; Posey, D.J.; Martin, A.; Ghuman, J.K. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am. J. Psychiatry 2005, 162, 1142–1148. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Campbell, M.; Anderson, L.T.; Meier, M.; Cohen, I.L.; Small, A.M.; Samit, C.; Sachar, E.J. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J. Am. Acad. Child Psychiatry 1978, 17, 640–655. [Google Scholar] [CrossRef] [Scilit]
- De Giacomo, A.; Craig, F.; Terenzio, V.; Coppola, A.; Campa, M.G.; Passeri, G. Aggressive behaviors and verbal communication skills in autism spectrum disorders. Glob. Pediatr. Health 2016, 3, 2333794X16644360. [Google Scholar] [CrossRef] [Scilit] [PubMed]
| Child Attending |
| The speech/language pathologists (SLP) must attract child’s attention before provoking a chance. |
| Obvious Chance |
| The question/education/opportunity to respond must be clear and suitable for the task. |
| Child Choice |
| The SLP should follow the child’s choice with tasks and actions. If child is not showing interest in the present task, SLP should effort to alter the practice. |
| Keep Tasks |
| The SLP should combine tasks the child can already complete with new tasks. |
| Conditional |
| Reinforcement must be depending on child’s behavior. The SLP’s response must be contingent upon the child’s response. |
| Natural |
| Reinforcement should be natural or right associated to the favorite behavior. |
| Depending on Challenges |
| Any target-directed effort to respond to questions, guidelines, or chances should be reinforced. |
| Variable | RIS Group (n = 17) Mean ± SD | PRT + RIS Group (n = 17) Mean ± SD | p |
|---|---|---|---|
| Age | 148.94 ± 29.41 | 144.70 ± 37.58 | 0.911 |
| MLU | 3.54 ± 0.60 | 3.23 ± 0.80 | 0.212 |
| Age of onset | 28.72 ± 4.21 | 29.68 ± 5.80 | 0.588 |
| Weight | 44.35 ± 12.31 | 43.82 ± 14.93 | 0.799 |
| Irritability | 2.72 ± 23.23 | 4.86 ± 23.05 | 0.897 |
| Lethargy/social withdrawal | 5.16 ± 30.41 | 28.52 ± 5.00 | 0.288 |
| Hyperactivity/noncompliance | 8.65 ± 22.94 | 8.75 ± 19.58 | 0.27 |
| Stereotypic behavior | 3.05 ± 17.23 | 4.45 ± 15.05 | 0.107 |
| Inappropriate speech | 1.76 ± 9.00 | 1.67 ± 9.94 | 0.285 |
| Variable | RIS Group (n = 17) Mean ± SD | PRT + RIS Group (n = 17) Mean ± SD | Mean Difference | p |
|---|---|---|---|---|
| MLU | 0.591 ± 3.60 | 0.832 ± 4.23 | 0.930 | ≤0.0001 |
| Irritability | 2.10 ± 13.76 | 4.80 ± 13.41 | 0.247 | 0.806 |
| Lethargy/social withdrawal | 4.84 ± 26.94 | 6.49 ± 20.88 | 4.299 | 0.001 |
| Hyperactivity/noncompliance | 6.39 ± 14.64 | 6.05 ± 12.88 | 0.431 | 0.631 |
| Stereotypic behavior | 2.34 ± 9.41 | 4.52 ± 8.05 | 0.002 | 0.999 |
| Inappropriate speech | 5.171 ± 94 | 4.471 ± 84 | 1.514 | 0.001 |
| Variable | Baseline Mean ± SD | Endpoint Mean ± SD | Follow-Up Mean ± SD | p |
|---|---|---|---|---|
| Irritability | ||||
| RIS | 2.72 ± 23.23 | 2.10 ± 13.76 | 1.39 ± 17.76 | ≤0.0001 |
| RIS + PRT | 23.05 ± 4.86 | 13.41 ± 4.80 | 16.82 ± 4.27 | |
| Lethargy/social withdrawal | ||||
| RIS | 30.41 ± 5.16 | 26.94 ± 4.84 | 27.94 ± 4.86 | ≤0.0001 |
| RIS + PRT | 28.52 ± 5.00 | 20.88 ± 6.49 | 21.35 ± 5.33 | |
| Hyperactivity/noncompliance | ||||
| RIS | 22.94 ± 8.65 | 14.46 ± 6.39 | 18.11 ± 7.00 | ≤0.0001 |
| RIS + PRT | 8.75 ± 19.58 | 6.05 ± 12.88 | 15.35 ± 6.48 | |
| Stereotypic behavior | ||||
| RIS | 17.23 ± 3.05 | 9.41 ± 2.38 | 12.47 ± 2.06 | ≤0.0001 |
| RIS + PRT | 15/05 ± 4.45 | 8/05 ± 4.52 | 10/94 ± 4.00 | |
| Inappropriate speech | ||||
| RIS | 9.00 ± 1.76 | 5.17 ± 1.94 | 6.58 ± 1.87 | ≤0.0001 |
| RIS + PRT | 9.94 ± 1.67 | 4/47 ± 1.84 | 6.64 ± 1.72 |
| Variables | RIS Group (n = 17) N (%) | PRT + RIS Group (n = 17) N (%) | p |
|---|---|---|---|
| Increased appetite | 4 (23.5) | 3(17.6) | 0.671 |
| Nausea | 2 (11.8) | 2(11.8) | 1 |
| Urinary problems | 3 (17.6) | 2(11.8) | 0.682 |
| Increased weight | 2 (11.8) | 2(11.8) | 1 |
| Sedation | 1 (5.9) | 1(5.9) | 1 |
| Dizziness | 1 (5.9) | 2(11.8) | 0.545 |
| Constipation | 3 (17.6) | 3(17.6) | 1 |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rezaei, M.; Moradi, A.; Tehrani-Doost, M.; Hassanabadi, H.; Khosroabadi, R. Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder. Children 2018, 5, 19. https://doi.org/10.3390/children5020019
Rezaei M, Moradi A, Tehrani-Doost M, Hassanabadi H, Khosroabadi R. Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder. Children. 2018; 5(2):19. https://doi.org/10.3390/children5020019
Chicago/Turabian StyleRezaei, Mohammad, AliReza Moradi, Mehdi Tehrani-Doost, HamidReza Hassanabadi, and Reza Khosroabadi. 2018. "Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder" Children 5, no. 2: 19. https://doi.org/10.3390/children5020019
APA StyleRezaei, M., Moradi, A., Tehrani-Doost, M., Hassanabadi, H., & Khosroabadi, R. (2018). Effects of Combining Medication and Pivotal Response Treatment on Aberrant Behavior in Children with Autism Spectrum Disorder. Children, 5(2), 19. https://doi.org/10.3390/children5020019
